Jounce Therapeutics, Inc. is a clinical stage immunotherapy company, which engages in developing treatments for cancer. The company is headquartered in Cambridge, Massachusetts and currently employs 141 full-time employees. The company went IPO on 2017-01-26. The company is engaged in the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long lasting benefits to patients through a biomarker-driven approach. Its pipeline is focused on product candidates to address PD-(L)1-inhibitor resistant and PD-(L)1 inhibitor sensitive tumors. Its program, JTX-8064, is a tumor-associated macrophage candidate from its Translational Science platform. JTX-8064 is a monoclonal antibody that binds to Leukocyte Immunoglobulin Like Receptor B2, (LILRB2), which is a cell surface receptor expressed on macrophages and other myeloid cells. JTX-1484 is a monoclonal antibody designed to block human Leukocyte Immunoglobulin Like Receptor B4, (LILRB4) on various myeloid cells. Its product candidate, vopratelimab, is a monoclonal antibody that binds to and activates T cell CO-Stimulator (ICOS). The company also develops JTX-1484 and JTX-2134 product candidates.

Industry: Biological Products, (No Diagnostic Substances) Peers: Anixa Biosciences Inc Brainstorm Cell Therapeutics Inc Capricor Therapeutics Inc CEL-SCI Corp Clovis Oncology, Inc. PARDES BIOSCIENCES, INC. Larimar Therapeutics Inc Matinas BioPharma Holdings Inc Werewolf Therapeutics Inc